EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Secondary Adrenal Insufficiency and Multisystem Endocrinopathy Following Immune Checkpoint Inhibitor Therapy

Olga Fedorova, Fuad AlSaraj

Annals of African Medicine · 2026

DOI: 10.4103/aam.aam_658_25 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of African Medicine, 2026. Verfasst von Olga Fedorova und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Mediclinic Parkview Hospital, Mediclinic Middle East, Dubai, UAE. Hauptthemen laut MEDLINE: Adrenal Insufficiency, Immune Checkpoint Inhibitors, Melanoma. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, including malignant melanoma. However, ICIs are associated with immune-related adverse events (irAEs), including hypophysitis, secondary adrenal insufficiency, thyroid disorders, and insulin-dependent diabetes. We present the case of a 60-year-old male with a history of autoimmune disorders, including primary hypothyroidism and giant-cell arteritis, who developed diabetes mellitus requiring insulin therapy after 6 weeks of treatment, eosinophilic asthma after 10 weeks, and who was admitted after 28 weeks of therapy with secondary adrenal insufficiency due to suspected ICI-associated isolated adrenocorticotrophic hormone (ACTH) deficiency. Pituitary magnetic resonance imaging showed no abnormalities. After several surgeries for melanoma and basal cell carcinoma, his current treatment includes hydrocortisone, levothyroxine, and insulin therapy. This case highlights the complexities in diagnosing and managing endocrinopathies associated with ICI therapy. As ICIs become more widely used, endocrine irAEs such as hypophysitis and isolated ACTH deficiency are expected to become increasingly common. A multidisciplinary approach is key to minimizing complications. While endocrine irAEs may require prompt hormone replacement, they rarely justify discontinuation of ICI therapy, whose benefits often outweigh the risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal InsufficiencyImmune Checkpoint InhibitorsMelanomaHumansMaleMiddle AgedHypophysitisHydrocortisoneEndocrine System DiseasesSkin NeoplasmsAdrenocorticotropic HormoneHypoglycemiaGenetic Diseases, Inborn

Stichwörter der Autor:innen

Checkpoint inhibitorsInhibiteurs de points de contrôlehypophysitehypophysitisimmune therapyimmunothérapieinsuffisance surrénalienne secondairemelanomamélanomesecondary adrenal insufficiency

Substanzen

Immune Checkpoint InhibitorsHydrocortisoneAdrenocorticotropic Hormone

Autor:innen und Institutionen

  • Department of Endocrinology, Mediclinic Parkview Hospital, Mediclinic Middle East, Dubai, UAE.

Zitieren

APA

Fedorova, O., & AlSaraj, F. (2026). Secondary Adrenal Insufficiency and Multisystem Endocrinopathy Following Immune Checkpoint Inhibitor Therapy. Annals of African Medicine. https://doi.org/10.4103/aam.aam_658_25

Vancouver

Fedorova O, AlSaraj F. Secondary Adrenal Insufficiency and Multisystem Endocrinopathy Following Immune Checkpoint Inhibitor Therapy. Annals of African Medicine. 2026. doi:10.4103/aam.aam_658_25

BibTeX
@article{Fedorova2026,
  author = {Fedorova, Olga and AlSaraj, Fuad},
  title = {Secondary Adrenal Insufficiency and Multisystem Endocrinopathy Following Immune Checkpoint Inhibitor Therapy},
  journal = {Annals of African Medicine},
  year = {2026},
  doi = {10.4103/aam.aam_658_25}
}
Kostenlos starten →